- Home
- QUBT vs PRAX Comparison
QUBT vs PRAX Comparison
Compare QUBT & PRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QUBT
- PRAX
- Stock Information
- Founded
- QUBT 2001
- PRAX 2015
- Country
- QUBT United States
- PRAX United States
- Employees
- QUBT N/A
- PRAX N/A
- Industry
- QUBT Computer Manufacturing
- PRAX Biotechnology: Pharmaceutical Preparations
- Sector
- QUBT Technology
- PRAX Health Care
- Exchange
- QUBT Nasdaq
- PRAX Nasdaq
- Market Cap
- QUBT 3.5B
- PRAX 4.0B
- IPO Year
- QUBT N/A
- PRAX 2020
- Fundamental
- Price
- QUBT $11.56
- PRAX $189.35
- Analyst Decision
- QUBT Strong Buy
- PRAX Strong Buy
- Analyst Count
- QUBT 3
- PRAX 13
- Target Price
- QUBT $23.67
- PRAX $228.69
- AVG Volume (30 Days)
- QUBT 31.0M
- PRAX 914.1K
- Earning Date
- QUBT 11-14-2025
- PRAX 11-05-2025
- Dividend Yield
- QUBT N/A
- PRAX N/A
- EPS Growth
- QUBT N/A
- PRAX N/A
- EPS
- QUBT N/A
- PRAX N/A
- Revenue
- QUBT $546,000.00
- PRAX $7,463,000.00
- Revenue This Year
- QUBT $11.21
- PRAX N/A
- Revenue Next Year
- QUBT $412.29
- PRAX $44.43
- P/E Ratio
- QUBT N/A
- PRAX N/A
- Revenue Growth
- QUBT 41.45
- PRAX 364.98
- 52 Week Low
- QUBT $4.37
- PRAX $26.70
- 52 Week High
- QUBT $27.15
- PRAX $206.71
- Technical
- Relative Strength Index (RSI)
- QUBT 41.97
- PRAX 58.39
- Support Level
- QUBT $9.50
- PRAX $160.11
- Resistance Level
- QUBT $11.81
- PRAX $192.70
- Average True Range (ATR)
- QUBT 1.23
- PRAX 15.20
- MACD
- QUBT 0.17
- PRAX -3.47
- Stochastic Oscillator
- QUBT 50.27
- PRAX 76.36
About QUBT Quantum Computing Inc.
Quantum Computing Inc is an integrated photonics and quantum optics technology company that provides accessible and affordable quantum machines to the world today. Its products are designed to operate at room temperature and low power at an affordable cost. The Company's portfolio of core technologies and products offer capabilities in the areas of high-performance computing, artificial intelligence, and cybersecurity, as well as remote sensing applications.
About PRAX Praxis Precision Medicines Inc.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.